Metformin Fails in T2DM Patient
Metformin Fails in T2DM Patient
Thank you for participating in this activity. Please take a moment to complete the evaluation and posttest. Upon achieving correct responses on at least 3 of the 4 posttest questions and completing the evaluation on the following pages, you will be eligible to receive a CME certificate.
After your completion of the evaluation and posttest, you will be asked to enter your contact information and the number of credits you wish to claim (up to 0.5 AMA PRA Category 1 Credit™). This information is for issuance and tracking of CME certificates only and is not associated with your evaluation responses or provided to third parties.
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, family physicians, general practitioners and healthcare professional who treat patients with diabetes.
Upon completion of this educational activity, learners will be able to:
- Identify appropriate second-line glucose-lowering agents for patients with type 2 diabetes
- Review relative risks and potential benefits of adding sulfonylureas, thiazolidinediones, and GLP-1 agents to T2DM monotherapy
- Differentiate appropriate second-line treatment choices for T2DM by considering specific patient characteristics
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The following faculty reported relevant financial relationships:
David A. D'Alessio, MD: Consultant for Merck, Novo Nordisk Inc., Ethicon, Mannkind, Wyeth, and Amylin; Research grants from Lilly, Ethicon, and Sanofi.
David M. Kendall, MD: As of July 2011, Kendall has been a full-time employee of Eli Lilly and Company.When this management option was written, Kendall received research support from Amylin Pharmaceuticals, Dexcom, Eli Lilly and Co, Medtronic/MiniMed, Merck, NIH-NHLBI, Novo Nordisk, Roche, Sanofi-Aventis; Consultant, Scientific and Clinical Advisory Board or Safety oversight activity and Educational Funding from Amylin Pharmaceuticals, Bayer Diabetes Care, Daiichi-Sankyo, Eli Lilly and Co., HealthPartners, Intarcia, Merck, Roche Genentech, Takeda, UnitedHealth Group
Spouse was, and is currently, an employee of Genentech (Roche).
All industry sponsored research activity, advisory/consultancy work and educational services were performed under contract directly to the non-profit Park Nicollet Institute and the International Diabetes Center in 2008-2009 and Dr. Kendall received no personal or direct compensation for these activities.
Kendall was Chief Scientific and Medical Officer of the American Diabetes Association (ADA). The views and opinions presented are his own, and do not necessarily reflect an official position of the ADA.
Charles McClave, MD: No relevant financial relationships reported
The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships: Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Endocrine Society and Knighten Health staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
- 0.50 AMA PRA Category 1 Credits™